Results 51 to 60 of about 3,775 (204)

Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection

Gut Microbes, 2022
In fecal microbiota transplantation (FMT) against recurrent Clostridioides difficile infection (CDI), clinical outcomes are usually determined after 8 weeks. We hypothesized that the intestinal microbiota changes earlier than this timepoint, and analyzed
Shaodong Wei, Martin Iain Bahl, Simon Mark Dahl Baunwall, Jens Frederik Dahlerup, Christian Lodberg Hvas, Tine Rask Licht   +5 more
doaj   +1 more source

Biovigilance in Faecal Microbiota Transplantation: 7‐Year Cohort Study and Framework for Microbiological Assessments of Infectious Adverse Events

United European Gastroenterology Journal, Volume 14, Issue 5, June 2026.
ABSTRACT Background and Aims Faecal microbiota transplantation (FMT) is increasingly used. However, no systematic approach exists to assess infectious risks after FMT, leading to underreporting. We evaluated infectious complications at the Netherlands Donor Feces Bank (NDFB) and proposed a structured biovigilance approach aligned with the EU Regulation
V. O. Chernova, J. van Prehn, B. Groenewegen, E. van Lingen, E. J. Kuijper, M. M. C. Lambregts, E. van Nood, G. Choi, M. D. Hazenberg, J. J. Keller, E. M. Terveer   +10 more
wiley   +1 more source

Kontrollierter Transport und lichtinduzierte Freisetzung von Magic Spot Nukleotiden in Escherichia coli

Angewandte Chemie, Volume 138, Issue 15, 6 April 2026.
We synthesized photocaged, clickable and isotope‐labeled “magic spot” Nucleotides and delivered them into Escherichia coli comparing different approaches. Light‐controlled release inside living cells enabled tracking of their conversion from pppGpp to ppGpp by capillary electrophoresis mass spectrometry and revealed their impact on the growth rate of a
Christoph Popp, Patrick Moser, Anselm Schwoerbel, Xinwei Liu, Johannes Freitag, Pinku Sarmah, Isabel Prucker, Robert Zscherp, Xuan Wang, Philipp Klahn, Hans‐Georg Koch, Gert Bange, Henning J. Jessen   +12 more
wiley   +1 more source

Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production. [PDF]

PLoS ONE, 2016
BACKGROUND:We have previously shown that fidaxomicin instillation prevents spore recovery in an in-vitro gut model, whereas vancomycin does not. The reasons for this are unclear.
Caroline H Chilton, Grace S Crowther, Helen Ashwin, Chris M Longshaw, Mark H Wilcox   +4 more
doaj   +1 more source

In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile

, 2023
International audienceBackground : Fidaxomicin is a first-line treatment for Clostridioides difficile infections (CDIs). Fidaxomicin resistance has rarely been reported in this urgent antimicrobial resistance threat as defined by the CDC. Objectives : To
Gaëtan Poulen, Barbut, Frédéric, Mark Wilcox, Cyril Anjou, Hélène Marchandin, Jane Freeman, Poulen, Gaëtan, Freeman, Jane, Frédéric Barbut, Wilcox, Mark, Anjou, Cyril, Hélène Jean-Pierre, Marchandin, Hélène, Jean-Pierre, Hélène   +13 more
core   +1 more source

Decreased warfarin effects in elder with recurrent Clostridium difficile infection during fidaxomicin therapy: a case report

Clinical Management Issues, 2015
Clostridium difficile infection is a disease with increasing incidence, particularly in high‑riskpatients such as the elderly, immunocompromised patients, etc. We report an unexpected decrease of International Normalized Ratio (INR) response to warfarin
Antonio Riccardo Buonuomo, Maria Alessandra Foggia, Emanuela Zappulo, Guglielmo Borgia, Ivan Gentile   +4 more
doaj   +1 more source

Clostridioides difficile Infection: Updates on Epidemiologic Patterns, Diagnostic Tools, and Treatment Modalities

Mediterranean Journal of Infection, Microbes and Antimicrobials, 2023
Clostridioides difficile is the predominant worldwide etiology of healthcare-associated diarrhea. Furthermore, C. difficile infections (CDIs) have been designated by the Centers for Disease Control and Prevention as an urgent threat, which is the highest
Lamiaa Abd El-Fattah MADKOUR
doaj   +1 more source

Controlled Delivery and Light‐Induced Release of Magic Spot Nucleotides in Escherichia coli

Angewandte Chemie International Edition, Volume 65, Issue 15, 6 April 2026.
We synthesized photocaged, clickable and isotope‐labeled “magic spot” Nucleotides and delivered them into Escherichia coli comparing different approaches. Light‐controlled release inside living cells enabled tracking of their conversion from pppGpp to ppGpp by capillary electrophoresis mass spectrometry and revealed their impact on the growth rate of a
Christoph Popp, Patrick Moser, Anselm Schwoerbel, Xinwei Liu, Johannes Freitag, Pinku Sarmah, Isabel Prucker, Robert Zscherp, Xuan Wang, Philipp Klahn, Hans‐Georg Koch, Gert Bange, Henning J. Jessen   +12 more
wiley   +1 more source

Ionomycin Exhibits Potent and Selective Bactericidal Activity Against Clostridioides difficile Through Calcium‐Dependent Membrane Disruption

MicrobiologyOpen, Volume 15, Issue 2, April 2026.
Ionomycin exhibits potent and selective bactericidal activity against Clostridioides difficile, rapidly reducing vegetative cells, toxin production, sporulation, and spore germination while sparing representative gut microbiota. Its activity is calcium‐dependent and mediated through disruption of bacterial membrane potential, highlighting ionomycin as ...
Ahmed A. Abouelkhair, Nader S. Abutaleb, Mohamed N. Seleem   +2 more
wiley   +1 more source

An Economic Analysis: Is Fidaxomicin Worth the Cost? [PDF]

Clinical Infectious Diseases, 2013
To the Editor— We recognize the efforts by Bartsch et al [1] to evaluate fidaxomicin (DIFICID). The conclusions drawn by the authors, however, warrant reexamination in light of numerous clinical and methodological problems. Clinically, the “all-or-none” treatment approach used in the decision model does not accurately represent real-world treatment ...
Shah, Hemal, Doyle, Joseph J., Belletti, Daniel A.   +2 more
openaire   +2 more sources